[{"orgOrder":0,"company":"OSE Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"OSE-127","moa":"monoclonal antibodies: interleukins","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for OSE-127

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OSE Immunotherapeutics

                          Country arrow
                          Boulder Peptide
                          Not Confirmed

                          OSE Immunotherapeutics

                          Country arrow
                          Boulder Peptide
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 11, 2021

                          Lead Product(s) : OSE-127

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OSE Immunotherapeutics

                          Country arrow
                          IFSCC
                          Not Confirmed

                          OSE Immunotherapeutics

                          Country arrow
                          IFSCC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 10, 2019

                          Lead Product(s) : OSE-127

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Servier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank